Pri-miR526b and Pri-miR655 Are Potential Blood Biomarkers for Breast Cancer.
biomarker
breast cancer
early detection
miRNA
plasma
pri-miRNA
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jul 2021
30 Jul 2021
Historique:
received:
12
07
2021
accepted:
28
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
We reported that two microRNAs, miR526b and miR655, are oncogenic in breast cancer (BC). Overexpression of these two miRNAs in poorly metastatic BC cells promotes aggressive BC phenotypes in vitro and in vivo. High expression of each miRNA was associated with poor patient survival. In this pilot biomarker study, we report for the first time that miRNA precursor RNAs (pri-miRNAs) are robust and sensitive biomarkers for BC, detectable in both human blood plasma and biopsy tissues. Pri-miRNA detection and quantification do not require a special enrichment procedure, thus reducing specimen quantity. Blood plasma samples from 90 malignant tumor-bearing patients and 20 benign lesion-bearing participants (control) were analyzed for pri-miRNA expression with a quantitative real-time polymerase chain reaction. Results revealed that normalized expressions of plasma pri-miR526b and pri-miR655 are significantly upregulated in malignancy compared to benign plasmas (
Identifiants
pubmed: 34359739
pii: cancers13153838
doi: 10.3390/cancers13153838
pmc: PMC8345356
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : RGPIN-2017-04787
Références
J Mol Diagn. 2013 Nov;15(6):827-34
pubmed: 23988620
Pathol Res Pract. 2017 Nov;213(11):1384-1387
pubmed: 28964576
ESMO Open. 2021 Feb;6(1):100039
pubmed: 33477007
Arthritis Res Ther. 2018 Mar 1;20(1):39
pubmed: 29490676
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277414
Sci Rep. 2018 Jan 10;8(1):327
pubmed: 29321644
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
PLoS One. 2010 Oct 20;5(10):e13515
pubmed: 20976003
Int J Genomics. 2020 Sep 7;2020:9514831
pubmed: 32964011
Sensors (Basel). 2017 Jul 05;17(7):
pubmed: 28678153
Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
PLoS One. 2012;7(3):e30679
pubmed: 22427800
CA Cancer J Clin. 2016 Sep;66(5):359-69
pubmed: 27175568
PLoS One. 2009 Nov 11;4(11):e7695
pubmed: 19907646
Ann Surg. 2010 Mar;251(3):499-505
pubmed: 20134314
Can J Public Health. 2018 Jan 22;108(5-6):e539-e545
pubmed: 29356661
Int J Mol Sci. 2019 Aug 19;20(16):
pubmed: 31430859
Chronic Dis Inj Can. 2011 Sep;31(4):152-6
pubmed: 21978638
Stem Cells. 2016 Sep;34(9):2290-305
pubmed: 27301070
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Coll Antropol. 2011 Mar;35(1):241-7
pubmed: 21661378
Front Oncol. 2015 May 26;5:115
pubmed: 26075182
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Invest Radiol. 1979 Mar-Apr;14(2):109-21
pubmed: 478799
Hum Mutat. 2009 Jan;30(1):79-84
pubmed: 18634034
J Hematol Oncol. 2015 Jul 10;8:83
pubmed: 26156517
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Mol Cancer Res. 2015 Jun;13(6):1022-33
pubmed: 25733698
Endocr Connect. 2017 Nov;6(8):614-624
pubmed: 28899898
Int J Mol Sci. 2018 Mar 29;19(4):
pubmed: 29596308
Theranostics. 2015 Jul 13;5(10):1122-43
pubmed: 26199650
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707933